Christy Jones - 24 Jun 2026 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Reporting relationship: Director
Issuer ticker: BBNX
Reported as of: 24 Jun 2026
Net transaction value: -$21,090
SEC form: 4
Accepted by SEC: 25 Jun 2026, 16:32:30 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Feider, Attorney-in-Fact

Key filing fact

Christy Jones filed Form 4 for Beta Bionics, Inc. (BBNX) on 25 Jun 2026.

Key facts

This page summarizes Christy Jones's Form 4 filing for Beta Bionics, Inc. (BBNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Jun 2026, 16:32.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: -$21,090.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002048467 Primary reporting owner

Jones Christy

Relationship: Director
Address: C/O BETA BIONICS, INC., 11 HUGHES, IRVINE
Signature: /s/ Stephen Feider, Attorney-in-Fact
Signature date: 25 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBNX transaction

Common Stock

Sale

Transaction value: $21,090
Shares: -1,406
Change %: -5.1%
Price: $15.00
Shares after: 25,994
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026.